Navigation Links
AMRI Burlington Receives DEA Approval to Handle Controlled Substances
Date:6/18/2013

ALBANY, N.Y., June 18, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that its Burlington, Mass., site has received approval to expand its current U.S. Drug Enforcement Administration (DEA) registration to handle Schedule 2 and 2N controlled substances. The license represents the DEA's acknowledgement of Burlington's physical security and quality systems, including inventory control and documentation.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO)

With its cGMP aseptic formulation and filling expertise, AMRI Burlington supports pre-clinical through commercial scale production of liquid-filled and lyophilized parenterals. The addition of Schedule 2 compounds to this registration allows Burlington to perform controlled substance work for its customers, both in the laboratory and on the engineering/production side.

Steven R. Hagen, Ph.D., Senior Vice President of Pharmaceutical Development and Manufacturing at AMRI, said, "As part of its fully integrated global contract services offering, AMRI has the expertise to support cGMP production for a wide spectrum of products across platform technologies, both at the small and large scale. The DEA's recognition of the security and documentation systems at the Burlington facility is just another example of how AMRI's formulation and filling capabilities can meet the various needs of the pharmaceutical and biotechnology industries."

Dr. Hagen continued, "Receiving approval from the DEA to handle controlled substances demonstrates AMRI's continued ability to offer compliant, quality manufacturing process options to our customers. Our expanded license allows us to
'/>"/>

SOURCE AMRI
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. UCSB professor receives award for graphene electronics research
2. Watsons Generic Yaz(R) Receives FDA Approval
3. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
4. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
5. MacroGenics Receives Milestone Payment as Part of Its Global DARTâ„¢ Alliance with Boehringer Ingelheim
6. Intimate Bridge 2 Conception, Inc. Receives $4.3M
7. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
8. BioNeutral Group Receives $400,000 in Equity Financing
9. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
10. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
11. Life Technologies Receives AFNOR Validation for Tests Designed to Detect Listeria Contamination in Food Samples
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Currently offering a comprehensive portfolio ... Weighing, Rice Lake, and Ohaus, Pipette.com has added ... Sartorius CPA Semi-Micro Balance is ideal for lab ... user-friendly laboratory balance. , Sartorius is a global ... balances are well known for their high performance, ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, announced today ... a Notice of Allowance for a composition of matter ... C. difficile program, SYN-004. This is Synthetic Biologics, ... the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... Oct. 20, 2014 Asterias Biotherapeutics, Inc. ... has signed a Notice of Grant Award (NGA) ... effective October 1, 2014.  The NGA provides for ... the release of additional grant funds pursuant to ... for clinical development of Asterias, product, AST-OPC1. The ...
Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... NeoGenomics, Inc. (OTC,Bulletin Board: NGNM) announced today that it ... May 7, 2008., The Company has scheduled a ... May 7, 2008, at 11:00 AM EDT. Interested investors ... minutes prior to the call. A replay of the ...
... Scientific,Corporation (NYSE: BSX ) announced today that ... issued its ruling in an,arbitration between the Company ... pursuant to the 2005 settlement agreement between,the companies, ... various U.S. and European patents held by Medinol. ...
... LEXINGTON, Mass., May 5 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... Phase III extension study of SUPPRELIN(R) LA (histrelin ... of central,precocious puberty or early onset puberty, at ... This study evaluated the two-year,safety and efficacy of ...
Cached Biology Technology:NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 3Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty 2Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty 3Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty 4Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty 5
(Date:10/16/2014)... October 16, 2014 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... technologies including Wocket™, the Smart Wallet, at the 13 ... is a leading global conference on the intersection of ... Mark Anderson , founder and publisher of the ...
(Date:10/15/2014)... University Mainz (JGU) as a full member, ensuring ... a significant nationwide standing in the field of ... Gutenberg University Mainz as a full member of ... and international competition for the best minds and ... proud that Mainz University has been recognized as ...
(Date:10/15/2014)... Geneticist Fred Alt will be awarded the 44th Rosenstiel ... University for his pioneering research exploring the mechanisms of ... and cancer cells. Alt is the second alumnus to ... the Nobel Prize in 2003. , Alt is the ... Genetics at Harvard Medical School and an investigator at ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
... that the extremely hot, dry and windy conditions on Black ... rolls, -similar to streamers of wind flowing through the air ... the first of its kind to produce such detailed, high-resolution ... for future fire management and warning systems. The work ...
... is a project that will require the cooperation ... and individuals. The 2012 American Chestnut Summit will ... and industry professionals to share the current state ... reintroduction of this species to eastern forests. The ...
... New Rochelle, NY, August 7, 2012The global market value of ... once therapeutics are approved that actually change the course of ... (GEN). The current therapeutic market is valued at $3 to ... or address the symptoms but do not alter the underlying ...
Cached Biology News:Unusual weather events identified during the Black Saturday bushfires 2GEN reports on recent progress in Alzheimer's research 2
Alexa Fluor 647 anti-mouse Qa-2...
... is the first fully genetically encoded fluorescent ... intracellular hydrogen peroxide (H2O2), one of the ... the basis of yellow fluorescent protein inserted ... protein OxyR (OxyR-RD), HyPer demonstrates submicromolar affinity ...
... siSolutions siRNA Custom Synthesis ... effective duplex RNA to knockdown ... 21-mers (19 RNA base pairs ... recently-published 27-mers, or other lengths ...
Alexa Fluor 647 anti-mouse Qa-2...
Biology Products: